ABSTRACT
Decreased autophagic flux in cardiomyocytes is an important mechanism by which the ß1-adrenoreceptor (ß1-AR) autoantibody (ß1-AA) induces heart failure. A previous study found that ß1-AA imparts its biological effects via the ß1-AR/Gs/AC/cAMP/PKA canonical signaling pathway, but PKA inhibition does not completely reverse ß1-AA-induced reduction in autophagy in myocardial tissues, suggesting that other signaling molecules participate in this process. This study confirmed that Epac1 upregulation is indeed involved ß1-AA-induced decreased cardiomyocyte autophagy through CE3F4 pretreatment, Epac1 siRNA transfection, western blot and immunofluorescence methods. On this basis, we constructed ß1-AR and ß2-AR knockout mice, and used receptor knockout mice, ß1-AR selective blocker (atenolol), and the ß2-AR/Gi-biased agonist ICI 118551 to show that ß1-AA upregulated Epac1 expression through ß1-AR and ß2-AR to inhibit autophagy, and biased activation of ß2-AR/Gi signaling downregulated myocardial Epac1 expression to reverse ß1-AA-induced myocardial autophagy inhibition. This study aimed to test the hypothesis that Epac1 acts as another effector downstream of cAMP on ß1-AA-induced reduction in cardiomyocyte autophagy, and ß1-AA upregulates myocardial Epac1 expression through ß1-AR and ß2-AR, and biased activation of the ß2-AR/Gi signaling pathway can reverse ß1-AA-induced myocardial autophagy inhibition. This study provides new ideas and therapeutic targets for the prevention and treatment of cardiovascular diseases related to dysregulated autophagy.
Subject(s)
Autoantibodies , Myocytes, Cardiac , Animals , Mice , Autoantibodies/adverse effects , Autoantibodies/immunology , Autophagy , Mice, Knockout , Myocytes, Cardiac/metabolism , Signal TransductionABSTRACT
Statin-induced autoimmune myositis (SIAM) represents a rare clinical entity that can be triggered by prolonged statin treatment. Its pathogenetic substrate consists of an autoimmune-mediated mechanism, evidenced by the detection of antibodies directed against the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR Ab), the target enzyme of statin therapies. To facilitate the diagnosis of nuanced SIAM clinical cases, the present study proposes an "experience-based" diagnostic algorithm for SIAM. We have analyzed the clinical data of 69 patients diagnosed with SIAM. Sixty-seven patients have been collected from the 55 available and complete case records regarding SIAM in the literature; the other 2 patients represent our direct clinical experience and their case records have been detailed. From the analysis of the clinical features of 69 patients, we have constructed the diagnostic algorithm, which starts from the recognition of suggestive symptoms of SIAM. Further steps provide for CK values dosage, musculoskeletal MR, EMG/ENG of upper-lower limbs and, Anti-HMGCR Ab testing and, where possible, the muscle biopsy. A global evaluation of the collected clinical features may suggest a more severe disease in female patients. Atorvastatin proved to be the most used hypolipidemic therapy.
Subject(s)
Autoimmune Diseases , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Myositis , Humans , Female , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Autoantibodies/adverse effects , Myositis/chemically induced , Myositis/diagnosis , Autoimmune Diseases/diagnosis , Autoimmune Diseases/drug therapy , AlgorithmsABSTRACT
Statin drugs are commonly used to decrease levels of triglycerides and cholesterol. Common side effects of this medication class are generally mild and include headache, nausea, diarrhea, and myalgia. Rarely, statins have been associated with autoimmune disease resulting in a potentially serious inflammatory myopathy known as statininduced immune-mediated necrotizing myopathy (IMNM). Here, we describe a case of statin-induced IMNM in a 66-year-old man placed on atorvastatin several months prior to CABG surgery. We review the relevant laboratory results, imaging, immunologic, histopathologic findings and treatment strategy of this important disorder.
Subject(s)
Autoimmune Diseases , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Muscular Diseases , Myositis , Male , Humans , Aged , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Muscular Diseases/chemically induced , Muscular Diseases/pathology , Autoantibodies/adverse effects , Myositis/chemically induced , Muscles/pathologyABSTRACT
BACKGROUND: Drug-induced immune thrombocytopenia (DITP) is a rare, but serious complication to a wide range of medications. Upon suspicion, one should do a thorough clinical evaluation following proposed diagnostic criteria and seek laboratory confirmation. If confirmed, it is important to ensure avoidance of the drug in the future. STUDY DESIGN AND METHODS: Herein, we describe a young adult male who experienced two bouts of severe thrombocytopenia following dental treatment. The thrombocytopenia was acknowledged due to unexpected hemorrhaging during the procedures. On both occasions, he was exposed to four different drugs, none commonly associated with DITP. After the second episode of severe procedural-related thrombocytopenia, an investigation into the cause was initiated. We describe the clinical approach to elucidate which of the four implicated drugs was responsible for thrombocytopenia and the laboratory work-up done to confirm that the reaction was antibody-mediated and identify the antibody's drug: glycoprotein specificity. An alternative drug was tested both in vivo and in vitro, to identify an option for future procedures. RESULTS: Sequential exposure revealed the local anesthetic substance articaine to induce thrombocytopenia. Laboratory work-up confirmed drug-dependent antibodies (DDAbs) with specificity for the glycoprotein Ib/IX complex, swiftly identified by a bead-based Luminex assay. Further investigations by monoclonal antibody immobilization of platelet antigens assay (MAIPA) revealed a probable GPIb binding site. An alternative local anesthetic, lidocaine, was deemed safe for future procedures. CONCLUSION: Articaine can induce rapid-onset, severe immune-mediated thrombocytopenia causing bleeding complications. A modified bead-based Luminex platelet antigen assay proved a useful addition in the DITP-investigation.
Subject(s)
Purpura, Thrombocytopenic, Idiopathic , Thrombocytopenia , Anesthetics, Local/adverse effects , Antibodies, Monoclonal , Autoantibodies/adverse effects , Blood Platelets , Carticaine/adverse effects , Humans , Male , Thrombocytopenia/therapyABSTRACT
Immune checkpoint inhibitors (ICIs) are complicated by immune-related adverse events (irAEs), such as myositis, myocarditis, and myasthenia gravis (MG). Anti-titin antibody and anti-voltage-gated potassium channel Kv1.4 antibody are anti-striated antibodies that are frequently detected in MG patients with myositis and/or myocarditis. However, the clinical relationship between positive anti-striated antibodies and irAEs of ICIs remains unknown. We herein report a case of nivolumab-induced myositis and myocarditis with positive anti-titin antibody and anti-voltage-gated potassium channel Kv1.4 antibody in a patient with non-small-cell lung cancer. We also review reported cases of positive anti-striated antibodies related to irAEs of ICIs.
Subject(s)
Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Myasthenia Gravis , Myocarditis , Myositis , Potassium Channels, Voltage-Gated , Autoantibodies/adverse effects , Carcinoma, Non-Small-Cell Lung/complications , Carcinoma, Non-Small-Cell Lung/drug therapy , Humans , Immune Checkpoint Inhibitors , Lung Neoplasms/complications , Lung Neoplasms/drug therapy , Myasthenia Gravis/complications , Myocarditis/chemically induced , Myocarditis/complications , Myocarditis/diagnosis , Myositis/chemically induced , Myositis/complications , Myositis/diagnosis , Nivolumab/adverse effectsABSTRACT
Seizures are a prominent feature in N-Methyl-D-Aspartate receptor antibody (NMDAR antibody) encephalitis, a distinct neuro-immunological disorder in which specific human autoantibodies bind and crosslink the surface of NMDAR proteins thereby causing internalization and a state of NMDAR hypofunction. To further understand ictogenesis in this disorder, and to test a potential treatment compound, we developed an NMDAR antibody mediated rat seizure model that displays spontaneous epileptiform activity in vivo and in vitro. Using a combination of electrophysiological and dynamic causal modelling techniques we show that, contrary to expectation, reduction of synaptic excitatory, but not inhibitory, neurotransmission underlies the ictal events through alterations in the dynamical behaviour of microcircuits in brain tissue. Moreover, in vitro application of a neurosteroid, pregnenolone sulphate, that upregulates NMDARs, reduced established ictal activity. This proof-of-concept study highlights the complexity of circuit disturbances that may lead to seizures and the potential use of receptor-specific treatments in antibody-mediated seizures and epilepsy.
Subject(s)
Autoantibodies/adverse effects , Synaptic Transmission , Animals , Anti-N-Methyl-D-Aspartate Receptor Encephalitis/chemically induced , Disease Models, Animal , Male , Rats , Rats, WistarABSTRACT
To date, no study has demonstrated that soluble Fas ligand (sFasL)-mediated inflammation is regulated via interaction with Fas in vivo. We found that FasL interacts specifically with tumor necrosis factor receptor superfamily (TNFRSF)10B, also known as death receptor (DR)5. Autoantibody-induced arthritis (AIA) was attenuated in FasL (Faslgld/gld)- and soluble FasL (FaslΔs/Δs)-deficient mice, but not in Fas (Faslpr/lpr and Fas-/-)- or membrane FasL (FaslΔm/Δm)-deficient mice, suggesting sFasL promotes inflammation by binding to a Fas-independent receptor. Affinity purification mass spectrometry analysis using human (h) fibroblast-like synovial cells (FLSCs) identified DR5 as one of several proteins that could be the elusive Fas-independent FasL receptor. Subsequent cellular and biochemical analyses revealed that DR5 interacted specifically with recombinant FasL-Fc protein, although the strength of this interaction was approximately 60-fold lower than the affinity between TRAIL and DR5. A microarray assay using joint tissues from mice with arthritis implied that the chemokine CX3CL1 may play an important downstream role of the interaction. The interaction enhanced Cx3cl1 transcription and increased sCX3CL1 production in FLSCs, possibly in an NF-κB-dependent manner. Moreover, the sFasL-DR5 interaction-mediated CX3CL1-CX3CR1 axis initiated and amplified inflammation by enhancing inflammatory cell influx and aggravating inflammation via secondary chemokine production. Blockade of FasL or CX3CR1 attenuated AIA. Therefore, the sFasL-DR5 interaction promotes inflammation and is a potential therapeutic target.
Subject(s)
Arthritis/immunology , Autoantibodies/adverse effects , Fas Ligand Protein/metabolism , Receptors, TNF-Related Apoptosis-Inducing Ligand/metabolism , Animals , Cell Line , Humans , Jurkat Cells , MiceABSTRACT
BACKGROUND: Podocytes embrace the glomerular capillaries with foot processes, which are interconnected by a specialized adherens junction to ultimately form the filtration barrier. Altered adhesion and loss are common features of podocyte injury, which could be mediated by shedding of cell-adhesion molecules through the regulated activity of cell surface-expressed proteases. A Disintegrin and Metalloproteinase 10 (ADAM10) is such a protease known to mediate ectodomain shedding of adhesion molecules, among others. Here we evaluate the involvement of ADAM10 in the process of antibody-induced podocyte injury. METHODS: Membrane proteomics, immunoblotting, high-resolution microscopy, and immunogold electron microscopy were used to analyze human and murine podocyte ADAM10 expression in health and kidney injury. The functionality of ADAM10 ectodomain shedding for podocyte development and injury was analyzed, in vitro and in vivo, in the anti-podocyte nephritis (APN) model in podocyte-specific, ADAM10-deficient mice. RESULTS: ADAM10 is selectively localized at foot processes of murine podocytes and its expression is dispensable for podocyte development. Podocyte ADAM10 expression is induced in the setting of antibody-mediated injury in humans and mice. Podocyte ADAM10 deficiency attenuates the clinical course of APN and preserves the morphologic integrity of podocytes, despite subepithelial immune-deposit formation. Functionally, ADAM10-related ectodomain shedding results in cleavage of the cell-adhesion proteins N- and P-cadherin, thus decreasing their injury-related surface levels. This favors podocyte loss and the activation of downstream signaling events through the Wnt signaling pathway in an ADAM10-dependent manner. CONCLUSIONS: ADAM10-mediated ectodomain shedding of injury-related cadherins drives podocyte injury.
Subject(s)
ADAM10 Protein/metabolism , Amyloid Precursor Protein Secretases/metabolism , Membrane Proteins/metabolism , Nephritis/metabolism , Nephrotic Syndrome/metabolism , Podocytes/metabolism , Podocytes/pathology , Renal Insufficiency, Chronic/metabolism , ADAM10 Protein/genetics , Amyloid Precursor Protein Secretases/genetics , Animals , Autoantibodies/adverse effects , Blood Urea Nitrogen , Cadherins/metabolism , Cell Adhesion , Cell Communication , Cell Membrane/metabolism , Cells, Cultured , Creatinine/urine , Disease Models, Animal , Female , Glomerular Filtration Barrier/pathology , Glomerular Filtration Barrier/physiopathology , Humans , Male , Membrane Proteins/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Nephritis/pathology , Nephrotic Syndrome/pathology , Podocytes/physiology , Proteomics , Tissue Array Analysis , Transcriptome , Wnt Signaling PathwayABSTRACT
Statins are widely used in the treatment of hypercholesterolemia. Muscle weakness and elevated creatine kinase (CK) are frequent side effects of statins with an incidence of about 15%. Statin-associated myopathy is more common in people who receive multiple drugs, the elderly or women but the mechanism underlying it is still unclear. These symptoms generally improve after drug discontinuation. However, there is a type of autoimmune mediated myopathy characterised by the persistence of muscle weakness and CK elevation after stopping statins. Herein, we discuss a case of autoimmune myopathy associated with statin exposure and responsive to immunossupresive drugs. The increased use of statins in recent years raises the importance of acquaintance with this disease in clinical practice.
Subject(s)
Autoimmune Diseases , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Muscular Diseases , Aged , Autoantibodies/adverse effects , Autoimmune Diseases/chemically induced , Autoimmune Diseases/diagnosis , Autoimmune Diseases/drug therapy , Female , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Muscular Diseases/chemically induced , Muscular Diseases/diagnosisABSTRACT
OBJECTIVE: Neuroinflammation associated with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis may facilitate seizures. We previously showed that intraventricular administration of cerebrospinal fluid from patients with anti-NMDAR encephalitis to mice precipitates seizures, thereby confirming that antibodies are directly pathogenic. To determine whether interleukin (IL)-1-mediated inflammation exacerbates autoimmune seizures, we asked whether blocking the effects of IL-1 by anakinra, a selective IL-1 receptor antagonist, blunts antibody-induced seizures. METHODS: We infused C57BL/6 mice intraventricularly with purified serum IgG from patients with anti-NMDAR encephalitis or monoclonal anti-NMDAR IgG; subdural electroencephalogram was continuously recorded. After a 6-day interval, mice received anakinra (25 mg/kg sc, twice daily) or vehicle for 5 days. Following a 4-day washout period, we performed behavioral tests to assess motor function, anxiety, and memory, followed by hippocampus tissue analysis to assess astrocytic (glial fibrillary acidic protein [GFAP]) and microglial (ionized calcium-binding adapter molecule [Iba]-1) activation. RESULTS: Of 31 mice infused with purified patient NMDAR-IgG (n = 17) or monoclonal NMDAR-IgG (n = 14), 81% developed seizures. Median baseline daily seizure count during exposure to antibodies was 3.9; most seizures were electrographic. Median duration of seizures during the baseline was 82.5 s. Anakinra administration attenuated daily seizure frequency by 60% (p = .02). Anakinra reduced seizure duration; however, the effect was delayed and became apparent only after the cessation of treatment (p = .04). Anakinra improved novel object recognition in mice with antibody-induced seizures (p = .03) but did not alter other behaviors. Anakinra reduced the expression of GFAP and Iba-1 in the hippocampus of mice with seizures, indicating decreased astrocytic and microglial activation. SIGNIFICANCE: Our evidence supports a role for IL-1 in the pathogenesis of seizures in anti-NMDAR encephalitis. These data are consistent with therapeutic effects of anakinra in other severe autoimmune and inflammatory seizure syndromes. Targeting inflammation via blocking IL-1 receptor-mediated signaling may be promising for developing novel treatments for refractory autoimmune seizures.
Subject(s)
Amnesia, Anterograde/drug therapy , Anticonvulsants/therapeutic use , Autoantibodies/adverse effects , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Receptors, Interleukin-1/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/immunology , Seizures/drug therapy , Amnesia, Anterograde/chemically induced , Animals , Astrocytes/drug effects , Astrocytes/metabolism , Autoantibodies/immunology , Electroencephalography , Hippocampus/drug effects , Hippocampus/metabolism , Humans , Male , Mice , Mice, Inbred C57BL , Microglia/drug effects , Microglia/metabolism , Open Field Test , Seizures/chemically inducedSubject(s)
Autoantibodies/adverse effects , Autoantibodies/immunology , Autoimmune Diseases/etiology , Autoimmune Diseases/immunology , COVID-19/complications , COVID-19/physiopathology , Models, Immunological , SARS-CoV-2/pathogenicity , Aging/immunology , Annexin A2/immunology , Autoantibodies/isolation & purification , Autoimmune Diseases/microbiology , Autoimmune Diseases/virology , B-Lymphocytes/immunology , B-Lymphocytes/pathology , Blood Coagulation/immunology , Blood Vessels/immunology , Blood Vessels/pathology , Brain/immunology , Brain/pathology , COVID-19/etiology , COVID-19/immunology , COVID-19/pathology , COVID-19/virology , Critical Illness , Cytokine Release Syndrome/complications , Cytokine Release Syndrome/immunology , Cytokine Release Syndrome/pathology , Cytokine Release Syndrome/physiopathology , Female , HLA-DRB1 Chains/immunology , Helicobacter pylori/immunology , Helicobacter pylori/pathogenicity , Herpesvirus 4, Human/immunology , Herpesvirus 4, Human/pathogenicity , Humans , Interferon Type I/antagonists & inhibitors , Interferon Type I/immunology , Male , Myocardium/immunology , Myocardium/pathology , Phospholipids/immunology , Racial Groups , SARS-CoV-2/immunology , SARS-CoV-2/isolation & purification , Sex Characteristics , Streptococcus pyogenes/immunology , Streptococcus pyogenes/pathogenicity , Time Factors , Post-Acute COVID-19 SyndromeABSTRACT
Non-human leukocyte antigen (HLA) antibodies have been implicated in heart transplantation rejection. However, targets of non-HLA antibodies remain elusive. Here, we utilized a panel of multiplex beads-based assay to determine the specificity of non-HLA antibodies following heart transplantation. We utilized a selected cohort of recipients who did not have HLA donor specific antibodies, but were diagnosed with antibody mediated rejection and treated for antibody mediated rejection. We found the presence of vimentin antibody was associated with treated antibody mediated rejection. Our results suggest that, in heart transplant recipients who are suspected of AMR but in the absence of HLA donor specific antibodies, non-HLA antibodies should be examined.
Subject(s)
Autoantibodies/adverse effects , Graft Rejection/immunology , Graft Rejection/therapy , HLA Antigens/immunology , Heart Transplantation/adverse effects , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Immunotherapy/methods , Transplant Recipients , Vimentin/immunology , Adult , Aged , Female , Follow-Up Studies , Graft Rejection/diagnosis , Graft Survival/immunology , Histocompatibility Antigens Class I/immunology , Histocompatibility Antigens Class II/immunology , Histocompatibility Testing/methods , Humans , Male , Middle Aged , Tissue Donors , Treatment OutcomeABSTRACT
Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) was first introduced in 2011 by Shoenfeld et al. and encompasses a cluster of related immune mediated diseases, which develop among genetically prone individuals as a result of adjuvant agent exposure. Since the recognition of ASIA syndrome, more than 4400 documented cases have been reported so far, illustrated by heterogeneous clinical manifestations and severity. In this review, five enigmatic conditions, including sarcoidosis, Sjögren's syndrome, undifferentiated connective tissue disease, silicone implant incompatibility syndrome (SIIS), and immune-related adverse events (irAEs), are defined as classical examples of ASIA. Certainly, these disorders have been described after an adjuvant stimulus (silicone implantation, drugs, infections, metals, vaccines, etc.) among genetically predisposed individuals (mainly the HLA-DRB1 and PTPN22 gene), which induce an hyperstimulation of the immune system resulting in the production of autoantibodies, eventually leading to the development of autoimmune diseases. Circulating autonomic autoantibodies in the sera of patients with silicone breast implants, as well as anatomopathological aspects of small fiber neuropathy in their skin biopsies have been recently described. To our knowledge, these novel insights serve as a common explanation to the non-specific clinical manifestations reported in patients with ASIA, leading to the redefinition of the ASIA syndrome diagnostic criteria.
Subject(s)
Adjuvants, Immunologic/adverse effects , Autoimmune Diseases , Drug-Related Side Effects and Adverse Reactions , Autoantibodies/adverse effects , Autoimmune Diseases/chemically induced , Autoimmune Diseases/complications , Breast Implants/adverse effects , Drug-Related Side Effects and Adverse Reactions/classification , Drug-Related Side Effects and Adverse Reactions/diagnosis , Drug-Related Side Effects and Adverse Reactions/etiology , Humans , Inflammation/chemically induced , Inflammation/complications , Silicones/adverse effects , SyndromeABSTRACT
BACKGROUND: Auto-antibodies to tumor suppressor p53 are found in a subset of patients with colorectal cancer. A recent prospective study in the United States has reported a significant 1.8-fold increased odds for colorectal cancer development with prediagnostic seropositivity to p53. In this study, we sought to examine this association in a U.S. colorectal cancer cohort consortium to evaluate the potential utility of p53 auto-antibodies as an early biomarker for colorectal cancer. METHODS: Auto-antibodies to p53 were measured in prediagnostic blood samples of 3,702 incident colorectal cancer cases and 3,702 controls, matched by age, race, and sex, from 9 U.S. prospective cohorts. The association of seropositivity to p53 with colorectal cancer risk, overall and by time between blood draw and diagnosis, was determined by conditional logistic regression. RESULTS: Overall, 5% of controls and 7% of cases were seropositive to p53, resulting in a statistically significant 33% increased colorectal cancer risk [odds ratio (OR), 1.33; 95% confidence interval (CI), 1.09-1.61]. By follow-up time, the association was only significant with colorectal cancer diagnoses within 4 years after blood draw (OR, 2.27; 95% CI, 1.62-3.19), but not thereafter (OR, 0.97; 95% CI, 0.76-1.24). CONCLUSIONS: In this large consortium of prospective cohorts, we found that prediagnostic seropositivity to tumor suppressor p53 was significantly associated with an over 2-fold increased odds of developing colorectal cancer within 4 years after blood draw. IMPACT: Our finding suggests that p53 seropositivity may not be a useful predictor of long-term colorectal cancer risk; however, it might be considered as a marker to aid in the early diagnosis of colorectal cancer.
Subject(s)
Autoantibodies/adverse effects , Colorectal Neoplasms/etiology , Colorectal Neoplasms/physiopathology , Tumor Suppressor Protein p53/adverse effects , Cohort Studies , Female , Humans , Male , Prospective Studies , United StatesABSTRACT
Blood glucose is of great importance to development and metabolic homeostasis in fetuses. Stimulation of harmful factors during gestation induces pathoglycemia. Angiotensin II type 1 receptor autoantibody (AT1-AA), a newly discovered gestational harmful factor, has been shown to induce intrauterine growth restriction in fetuses and glucose disorders in adults. However, whether and how AT1-AA influences the blood glucose level of fetuses during gestation is not yet clear. The purpose of the current study was to observe the fetal blood glucose level of AT1-AA-positive pregnant rats during late pregnancy and to determine the roles that hepatic glucose transporters play in this process. We established AT1-AA-positive pregnant rats by injecting AT1-AA into the caudal veins of rats in the 2nd trimester of gestation. Although the fetal blood glucose level in the 3rd trimester of gestation decreased, hepatic glucose uptake increased detected. Through separating membrane and cytosolic proteins, we demonstrated that both the expression and membrane transport ratio of glucose transporter 1 (GLUT1), which is responsible for glucose transport in fetal hepatocytes, were upregulated, accompanied by increased expression of N-glycosyltransferase STT3A, which contributes to the N-glycosylation of GLUT1. In vitro, we identified that AT1-AA increased glucose uptake, the expression and membrane transport ratio of GLUT1 and the expression of STT3A in HepG2 cell lines via separating membrane and cytosolic proteins and immunofluorescence, resulting in the decreased glucose content in the medium. The GLUT1 inhibitor WZB117 reversed the decreases in glucose content in the medium, the increases in glucose uptake, the increases in the expression and membrane transport ratio of GLUT1 caused by AT1-AA. The N-glycosyltransferase inhibitor NGI as well as si-STT3A reversed the AT1-AA-induced upregulation of the STT3A-GLUT1-glucose uptake effect. This study demonstrates that AT1-AA lowers the blood glucose level of fetuses via the STT3A-GLUT1-glucose uptake axis in liver.
Subject(s)
Autoantibodies/physiology , Glucose/metabolism , Hypoglycemia/etiology , Liver/metabolism , Receptor, Angiotensin, Type 1/immunology , Animals , Autoantibodies/adverse effects , Embryo, Mammalian , Female , Fetus/immunology , Fetus/metabolism , Glucose Transporter Type 1/metabolism , Hep G2 Cells , Hexosyltransferases/metabolism , Humans , Hypoglycemia/immunology , Hypoglycemia/metabolism , Liver/immunology , Male , Membrane Proteins/metabolism , Pregnancy , Rats , Rats, Sprague-Dawley , Signal TransductionABSTRACT
Thyroid autoimmunity (TAI) is prevalent amongst women of reproductive age. TAI describes the presence of circulating anti-thyroid autoantibodies that are targeted against the thyroid, with or without thyroid dysfunction. Thyroid peroxidase antibodies (TPOAb) are the most common anti-thyroid autoantibodies. Around 10% of biochemically euthyroid individuals also have an elevated TPOAb titre. Many studies have linked the presence of TPOAb to adverse maternal and fetal outcomes in pregnancy, in particular miscarriage and pre-term birth, even in the absence of thyroid dysfunction. The causal pathway is poorly understood and few trials have looked to find treatments to reduce adverse outcomes. This review discusses in detail the associated adverse outcomes of TPOAb in pregnancy and the results of trials exploring methods to reduce such outcomes. Recommendations for counselling and monitoring of women with TPOAb and suggested areas for future work are also outlined.
Subject(s)
Autoantibodies/blood , Pregnancy Complications/diagnosis , Pregnancy Outcome , Thyroid Diseases/blood , Thyroid Diseases/diagnosis , Abortion, Spontaneous/etiology , Abortion, Spontaneous/immunology , Autoantibodies/adverse effects , Autoantibodies/analysis , Autoimmunity/physiology , Female , Humans , Hypothyroidism/blood , Hypothyroidism/immunology , Pregnancy , Pregnancy Complications/blood , Pregnancy Complications/epidemiology , Pregnancy Complications/immunology , Pregnancy Outcome/epidemiology , Thyroid Diseases/epidemiology , Thyroid Diseases/immunologyABSTRACT
The concept that exposure in utero to maternal anti-brain antibodies contributes to the development of autism spectrum disorders (ASD) has been entertained for over a decade. We determined that antibodies targeting Caspr2 are present at high frequency in mothers with brain-reactive serology and a child with ASD, and further demonstrated that exposure in utero to a monoclonal anti-Caspr2 antibody, derived from a mother of an ASD child, led to an-ASD like phenotype in male offspring. Now we propose a new model to study the effects of in utero exposure to anti-Caspr2 antibody. Dams immunized with the extracellular portion of Caspr2 express anti-Caspr2 antibodies throughout gestation to better mimic the human condition. Male but not female mice born to dams harboring polyclonal anti-Caspr2 antibodies showed abnormal cortical development, decreased dendritic complexity of excitatory neurons and reduced numbers of inhibitory neurons in the hippocampus, as well as repetitive behaviors and impairments in novelty interest in the social preference test as adults. These data supporting the pathogenicity of anti-Caspr2 antibodies are consistent with the concept that anti-brain antibodies present in women during gestation can alter fetal brain development, and confirm that males are peculiarly susceptible.
Subject(s)
Autism Spectrum Disorder/genetics , Autoantibodies/immunology , Membrane Proteins/genetics , Nerve Tissue Proteins/genetics , Neurogenesis/genetics , Animals , Antibodies, Anti-Idiotypic/genetics , Antibodies, Anti-Idiotypic/immunology , Autism Spectrum Disorder/immunology , Autism Spectrum Disorder/physiopathology , Autoantibodies/adverse effects , Behavior, Animal , Brain/immunology , Brain/pathology , Disease Models, Animal , Female , Hippocampus/immunology , Hippocampus/pathology , Humans , Male , Maternal Inheritance/genetics , Maternal Inheritance/immunology , Maternal-Fetal Relations , Membrane Proteins/immunology , Mice , Nerve Tissue Proteins/immunology , Neurogenesis/immunology , Problem BehaviorABSTRACT
Rationale: Inflammatory heart disorders are among the causes of human death. The causative factors of heart inflammation are to be further elucidated. House dust mite (HDM)-derived protein antigens are involved in the pathogenesis of many human diseases. This study aims to investigate the role of HDM-specific autoantibodies in the pathogenesis of heart inflammation. Methods: Human heart tissue samples were obtained from surgically removed hearts in heart transplantation. The interaction of the heart tissues with HDM-specific antibodies was assessed by pertinent immune analysis. The role of HDM-specific autoantibodies in the induction of heart inflammation was assessed with a murine model. Results: HDM-specific IgG (mIgG) was detected in the serum of patients with myocarditis (Mcd); the mIgG titers were positively correlated with the neutrophil counts in the heart tissues. The mIgG specifically bound to keratin-10 (KRT10) in heart vascular endothelial cells and the heart tissue protein extracts. The amounts of C3a, C5a and C5b-9 were increased in the mouse heart tissues after exposing to mIgG. In the presence of the complement-containing serum, mIgG bound cardiovascular epithelial monolayers to impair the barrier functions. Administration of mIgG or HDM induced the Mcd-like inflammation in the heart, in which neutrophils were the dominant cellular components in the infiltration of inflammatory cells. Conclusions: Mcd patients with neutrophilic inflammation in the heart had higher serum levels of mIgG. The mIgG bound heart endothelial cells to impair the endothelial barrier functions and induce neutrophilic inflammation in the heart.
Subject(s)
Allergens/adverse effects , Autoantibodies/blood , Myocarditis/immunology , Neutrophils/metabolism , Pyroglyphidae/immunology , Adult , Allergens/immunology , Animals , Autoantibodies/adverse effects , Complement System Proteins/metabolism , Disease Models, Animal , Female , Humans , Immunoglobulin G/blood , Keratin-10/metabolism , Male , Mice , Myocarditis/blood , Myocarditis/etiology , Young AdultABSTRACT
We report a 65-year-old man with autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A) who presented with gait disturbance that he had experienced for approximately half a year. On neurological examination, he displayed spastic paraplegia and autonomic dysfunctions including dysuria and constipation. Spinal cord magnetic resonance imaging showed longitudinally extensive spinal cord lesions (LESCLs) extending from the cervical to the thoracic cords. The patient was negative for anti-myelin oligodendrocyte glycoprotein and anti-aquaporin 4 antibodies. Treatment with corticosteroids and intravenous immunoglobulin resulted in a clinical improvement. It is important to distinguish GFAP-A from slowly progressive myelitis with LESCLs.